Quick Answer
KESTRA MEDICAL TECHNOLOGIES, LTD. reported Cash and Equivalents of $237.59 million for fiscal year 2025.
KESTRA MEDICAL TECHNOLOGIES, LTD. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $237.59M | +2780.3% |
| 2024 | $8.25M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| January 31, 2026 | $291.32M | +436.0% | +66.1% |
| October 31, 2025 | $175.42M | +128.1% | -12.8% |
| July 31, 2025 | $201.21M | +101.3% | -15.3% |
| April 30, 2025 | $237.59M | — | +337.1% |
| January 31, 2025 | $54.35M | — | -29.3% |
| October 31, 2024 | $76.92M | — | -23.1% |
| July 31, 2024 | $99.97M | — | — |
- KESTRA MEDICAL TECHNOLOGIES, LTD. showed an increase of +2780.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2024–2025 period, KESTRA MEDICAL TECHNOLOGIES, LTD.’s cash and equivalents has grown by 2780.3% (from $8.25 million to $237.59 million).
- The most recent figure is from KESTRA MEDICAL TECHNOLOGIES, LTD.’s fiscal year 2025 report (Form 10-K), filed with the SEC on July 17, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: